Understanding JAK inhibitor toxicity - 17/10/25
Doi : 10.1016/j.jaad.2025.07.024
Athira Sivadas, BS a, Kevin W. Byram, MD b, Manuel Valdebran, MD c, Tyler Beck, MD, PhD d, ⁎ 
a Vanderbilt University School of Medicine, Nashville, Tennessee
b Department of Rheumatology, Vanderbilt University Medical Center, Nashville, Tennessee
c Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina
d Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee
∗Correspondence to: Tyler Beck, MD, PhD, Department of Dermatology, Vanderbilt University Medical Center, 1161 21st Ave S, Nashville, TN 37232Department of DermatologyVanderbilt University Medical Center1161 21st Ave SNashvilleTN37232
Key words : cheminformatics, drug discovery, Janus kinase, pharmacology, toxicity
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
|
| Data availability statement: The raw data used to generate the results in this study can be found in the Supplementary Appendix, available via Mendeley at bs763khc3v.1. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 93 - N° 5
P. e199-e200 - novembre 2025 Retour au numéro
Article précédent
- Commentary on “Hormone therapy and increased risk of psoriasis in women”
- Ching-Ting Ting, Brian Shiian Chen, James Cheng-Chung Wei
- November 2025 Iotaderma (#381)
- Robert I. Rudolph
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?